Compare ALIT & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALIT | ZVRA |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | United States | United States |
| Employees | N/A | 61 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 568.2M | 562.2M |
| IPO Year | 2020 | 2015 |
| Metric | ALIT | ZVRA |
|---|---|---|
| Price | $16.98 | $9.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $3.75 | ★ $23.00 |
| AVG Volume (30 Days) | 714.3K | ★ 1.5M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 21.33% | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | N/A | ★ 0.60 |
| Revenue | ★ $2,262,000,000.00 | $106,470,000.00 |
| Revenue This Year | N/A | $37.27 |
| Revenue Next Year | $0.14 | $53.42 |
| P/E Ratio | ★ N/A | $16.05 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $0.48 | $7.16 |
| 52 Week High | $23.68 | $15.04 |
| Indicator | ALIT | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 56.14 | 29.41 |
| Support Level | $1.12 | $9.53 |
| Resistance Level | $23.68 | $11.07 |
| Average True Range (ATR) | 1.71 | 0.57 |
| MACD | -0.90 | -0.39 |
| Stochastic Oscillator | 2.91 | 10.87 |
Alight Inc is a technology-enabled services company delivering human capital management solutions to many complex organizations. This includes the implementation and administration of employee benefits (e.g., health, wealth, and leave benefits) solutions, which currently operate under one reportable segment, Employer Solutions. The Employer Solutions segment is driven by the Alight Worklife platform, and includes integrated benefits administration, healthcare navigation, financial well-being, leave of absence management, and retiree healthcare. Geographically, the company generates the majority of its revenue from the United States.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.